Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

A study of 1.2 million Danish children found no link between vaccines containing aluminum and an elevated risk for 50 ...

Moderna's COVID-19 vaccine has received full approval from the U.S. Food and Drug Administration (FDA) for use in children ...

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 percent higher in participants who were aged 65 years or older. Previous trial ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus challenges when combined with a mucosal adjuvant that enhances the ...

The trial tested Moderna’s shot, codenamed mRNA-1010, against four marketed vaccines developed by GSK to determine if the experimental shot could reduce incidence of flu.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases.

MIT's new dual-adjuvant vaccine offers strong HIV protection with a single dose, potentially aiding in the fight against challenging viruses.

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose. By combining two immune-boosting adjuvants alum ...